Patents by Inventor Arthur E. Frankel

Arthur E. Frankel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200129570
    Abstract: The present invention includes compositions and methods for increasing an efficacy of an immune checkpoint inhibitor comprising: identifying a human patient in need of treatment for a melanoma; providing the human patient with an effective amount of the immune checkpoint inhibitor; and providing the human patient with at least one of: a probiotic bacteria, a prebiotic agent, or a xenobiotic agent, in the amount is effective to increase the potency of the immune checkpoint inhibitor against the melanoma.
    Type: Application
    Filed: June 1, 2018
    Publication date: April 30, 2020
    Inventors: Arthur E. Frankel, Andrew Y. Koh
  • Publication number: 20190169251
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: February 8, 2019
    Publication date: June 6, 2019
    Applicant: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Patent number: 10273299
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: April 30, 2019
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Arthur E. Frankel, Yunpeng Su, Brad St. Croix, Stephen H. Leppla
  • Patent number: 10259853
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Publication number: 20180022788
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: March 10, 2017
    Publication date: January 25, 2018
    Applicant: SCOTT & WHITE MEMORIAL HOSPITAL
    Inventor: Arthur E. Frankel
  • Patent number: 9631006
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: April 25, 2017
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Publication number: 20160319016
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Application
    Filed: April 4, 2016
    Publication date: November 3, 2016
    Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Arthur E. FRANKEL, Yunpeng SU, Brad ST.CROIX, Stephen H. LEPPLA
  • Patent number: 9321820
    Abstract: The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: April 26, 2016
    Assignees: The Regents of the University of Colorado, Scott & White Healthcare
    Inventors: Thomas Flaig, Arthur E. Frankel, Andrew Thorburn, Michael L. Glode
  • Patent number: 9309322
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: April 12, 2016
    Assignee: Scott & White Healthcare (SWH)
    Inventors: Arthur E. Frankel, Yunpeng Su, Brad St. Croix, Stephen H. Leppla
  • Publication number: 20160024167
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: July 17, 2015
    Publication date: January 28, 2016
    Applicant: SCOTT & WHITE MEMORIAL HOSPITAL
    Inventor: Arthur E. Frankel
  • Patent number: 9181317
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: November 10, 2015
    Assignee: SCOTT & WHITE MEMORIAL HOSPITAL
    Inventor: Arthur E. Frankel
  • Publication number: 20130323173
    Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
    Type: Application
    Filed: November 14, 2011
    Publication date: December 5, 2013
    Applicant: The Government of the United States of America, as Represented by the Secretary, Department of Healt
    Inventors: Arthur E. Frankel, Yuripeng Su, Brad St. Croix
  • Publication number: 20130315860
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: May 17, 2013
    Publication date: November 28, 2013
    Applicant: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Patent number: 8470307
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: February 9, 2009
    Date of Patent: June 25, 2013
    Assignee: Scott & White Memorial Hospital
    Inventor: Arthur E. Frankel
  • Publication number: 20120232010
    Abstract: The present invention provides methods and compositions for treating bladder cancer. In particular, the present invention provides a fusion protein comprising a toxin moiety that is linked to an epithelial growth factor (EGF) moiety. The toxin moiety and the EGF moiety can be linked optionally via a linker. Typically, the fusion protein is administered intravesically into the cancerous bladder.
    Type: Application
    Filed: October 14, 2010
    Publication date: September 13, 2012
    Applicant: The Regents of the University of Colorado, a body corporate
    Inventors: Thomas Flaig, Arthur E. Frankel, Andrew Thorburn, L.Michael Glode, Jung Hee Woo, David Neville
  • Patent number: 7763242
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: July 27, 2010
    Assignees: Scott and White Memorial Hospital, Scott, Sherwood and Brindley Foundation
    Inventor: Arthur E. Frankel
  • Publication number: 20090232767
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: February 9, 2009
    Publication date: September 17, 2009
    Inventor: Arthur E. Frankel
  • Publication number: 20080138313
    Abstract: The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and/or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells.
    Type: Application
    Filed: September 7, 2007
    Publication date: June 12, 2008
    Inventor: Arthur E. Frankel
  • Patent number: 6060066
    Abstract: A method for treating a tumor is provided, which comprises the steps of preliminarily immunizing a patient in need of antitumor treatment with a toxin or toxin surrogate vaccine in an amount which is effective to generate an immune response to the toxin in the patient, thereby providing systemic protection from the toxin to the patient, and subsequently administering the toxin to the patient in an amount which is effective to kill tumor cells. The toxin may be any suitable toxin, for example ricin, abrin, gelonin or diphtheria.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: May 9, 2000
    Assignee: Novavax, Inc.
    Inventors: Paul V. Lemley, Jr., Arthur E. Frankel
  • Patent number: 5667786
    Abstract: A method for treating a tumor is provided, which comprises the steps of preliminarily immunizing a patient in need of antitumor treatment with a toxin or toxin surrogate vaccine in an amount which is effective to generate an immune response to the toxin in the patient, thereby providing systemic protection from the toxin to the patient, and subsequently administering the toxin to the patient in an amount which is effective to kill tumor cells. The toxin may be any suitable toxin, for example ricin, abrin, gelonin or diphtheria.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 16, 1997
    Assignee: Novavax, Inc.
    Inventors: Paul V. Lemley, Jr., Arthur E. Frankel